Health
DARE-19: No significant decrease in major events; dapagliflozin well tolerated in COVID-19 – Healio
The SGLT2 inhibitor dapagliflozin did not significantly reduce risk for organ failure or death or improve recovery among adults hospitalized with COVID-19 vs. placebo,…
Source/Disclosures
Source: Kosiborod M, et al. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
Disclosures:
The DARE-19 trial was funded by AstraZeneca. Kosiborod reports he received grants or advisory board, consultant or speaking fees from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk…
-
Noosa News19 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General18 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
General20 hours agoPerth man charged after investigation into organised crime and tobacco store attacks
-
General10 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging